EANM 2017 Setting new standards with molecular imaging.

European Association of Nuclear Medicine Annual Meeting

October 21-25, 2017
Technical Exhibition: October 22-24, 2017
Siemens Healthineers Hall X4, Booth #401

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Visit the booth to see live demos and learn more about all our products including the recently introduced Symbia Intevo Bold.^TM1

The future of PET/CT is here.
See it unveiled.
Sunday, October 22nd
9:45 a.m., Hall X4,
Siemens Healthineers booth 401

Siemens Healthineers Lunch Symposium
Leading experts in molecular imaging will share insights into the most recent advances in SPECT/CT and PET/CT.
Monday, October 23, 2017
1:00 p.m.-2:30 p.m., Hall K

Product Highlights

PET/CT

The future of PET/CT

The future of PET/CT will create real clinical, operational and financial benefits for our customers.

Learn more

Biograph Horizon Flow edition

The Biograph Horizon^TM Flow edition² with FlowMotion^TM technology enables standardized indication-based protocols, adjusted to the patient’s anatomy, all in a single scan.

Biograph mCT Flow

Biograph mCT Flow^TM with FlowMotion technology combines our standard-setting PET/CT with a unique system design that enables continuous motion of the patient table—allowing increased image quality, greater patient comfort, better performance and expanded versatility.

Learn more

FlowMotion Technology

FlowMotion continuous bed motion technology, enables standardized indication-based protocols, adjusted to the patient’s anatomy, all in a single scan–-personalizing the patient experience while optimizing the workflow.

PET/MR

Biograph mMR

With Biograph mMR MR/PET you can set the pace in diagnostic imaging, by combining leading 3T MRI performance with proven molecular imaging, fully integrated in one system.

Learn more

SPECT/CT

Symbia Intevo Bold

A better image for every body.³ For those who want more from SPECT/CT. We made high-performance CT even better with the Symbia Intevo Bold.™²

Learn more

Symbia Intevo

Priorities in healthcare are shifting. Better care no longer means more care. It means more effective care. Now, you can discover expanded clinical reach and a higher standard of care and distinction for your organization−with the hybrid SPECT/CT technology of Symbia Intevo.^TM

Learn more

xSPECT Technologies

Expanded xSPECT Quant^TM2 now offers automated, accurate and reproducible quantification of ⁹⁹mTc, ¹²³I, ¹⁷⁷Lu⁴ and ¹¹¹In. This extends the use of advanced SPECT/CT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, neuroblastoma and metastatic prostate cancer. xSPECT Bone^TM provides higher resolution and increased clinical detail to support physicians’ ability to more confidently characterize disease state. xSPECT,™ the true integration of SPECT and CT.

Reading Solutions

syngo.via for MI

Save time, cost and effort with one reading solution engineered for greater productivity and accuracy: syngo^® .via for Molecular Imaging is available for both PET/CT, SPECT and SPECT/CT.

Learn more

Abstracts

Title	Topic Area	Authors
Assessment of whole-body scatter correction for Ga-68 PSMA PETCT	PET	Harshali Bal, Inki Hong, Florian Buther, Mehmet Aykac, Klaus Schafers, Maurizio Conti
First human images from a next generation SiPM based PET/CT system	PET	Mike Casey, Ziad Burbar, Harold Rothfuss, Vladimir Panin, Deepak Bharkhada, William Howe, Yong Bradley
Quantitative Y-90 PET for dosimetry applications	PET	Yuni Dewaraja, Hongki Lim, Neal Clinthorne, Jeffrey Fessler, Yuni Dewaraja, Maurizio Conti
Using EQ.PET to reduce reconstruction-dependent variation in FDG PET brain imaging	PET	M. Vanhoutte, R. Lopes, F. Semah, R. Fahmi
Comparison of an image-based to an atlas-based volume of interest for DaTScan quantification	PET	Rachid Fahmi, Sven Zuehlsdorff
Estimation and reliability of myocardial blood flow after motion correction with dynamic PET using a Bayesian framework	PET	Antione Saillant, Kimberley Saint, Matthew Memmott, Ian Armstrong, Vijay Shah, Sven Zuehlsdorff, Jérôme Declerck, Mark Jenkinson, Michael Chappell
Robustness of EQ-PET SUV harmonization to tumor-to-background variation	PET	Bruce Spottiswoode, Vittoria Mattoli, Margherita Milite, Maria Lucia Calcagni, Alessandro Giordano, Luca Indovina
Quantitative SPECT Neuroimaging using a Data Driven Estimation of Attenuation from the Projection Data Alone	SPECT	Xinhong Ding, A. Hans Vija
Assessment of Statistical Dose Uncertainty Propagation for Lu1771 SPECT Imaging with an Automated Internal Dosimetry Research Tool as a result of fast SPECT Acquisition Protocols	SPECT	A. Hans Vija, Michal Cachovan
Diagnostic value of quantitative 99mTc-DPD-SPECT/CT for the detection of prosthetic loosening in patients with hip and knee joint replacement.	SPECT	Martin Braun, Michal Cachovan, Geert Pagenstert, Damian Wild, Martin Kretzschmar
Assessment of Dose Uncertainty Propagation using standardized Quantitative Lu177⁴SPECT Imaging and an Automated Internal Dosimetry Research Tool	SPECT	A. Hans Vija, Michal Cachovan
First Clinical Experience with Ultra-High Resolution Multi-Focal Collimators for Tc-99m-PSMA Imaging	SPECT	Christian Schmidkonz, Claudia Hollweg, James C. Sanders, Michael Beck, Daniela Schmidt, A. Hans Vija, Torsten Kuwert, Philipp Ritt
xSPECT derived absolute SUV: An emerging accurate tool for I-123-ioflupane analysis	SPECT	M. Jreige, F. Tabotta, M. Nicod Lalonde, R. Fahmi, N. Schaefer, G. Allenbach, J. O. Prior

Key Presentations

Plenary 1 – Sunday, October 22
	Hall A, 10:00-11:15	Theranostic Developments for Prostate Cancer (incl. Marie Curie Lecture) Chairs: Dr. Kristoff Myulle, Prof. Francesco Giammarile Prof. Jochen Walz (FR): Clinical Aspects Prof. Ken Herrmann (DE): PSMA Imaging – Which Knife is the Sharpest? Prof. Uwe Haberkorn (DE): Marie Curie Lecture: PSMA Labelled with Alfa-Emitters
Sunday, October 22, 2017
	08:00 - 09:30	CME 1-Physics-Challenges and Solutions for MR-Based Attenuation Correction of PET
	08:00 - 08:30	Volkmar Schulz (Aachen): Introduction to MR-Based AC
	08:30 - 09:00	Ninon Burgos (London): MR Based Attenuation Correction for Brain
	09:00 – 09:30	Georg Schramm (Leuven): MR Based Attenuation Correction for the Body
Monday, October 23, 2017
	08:00 - 09:30	CME 5-Radiopharmacy/ Drug Development/ Radionuclide Therapy/ SNMMI-Theranostics and Companion Drugs
	08:00 - 08:30	08:00 - 08:30 Hans-Jürgen Wester (Munich): Theranostic Concepts, Exemplified on PSMA and CXCR4
	08:00 - 08:30	Karl Herholz (Manchester): Brain PET and SPECT in Patients with Fronto-Temporal Dementia
	08:00 - 09:30	Committee Symposium 2-Neuroimaging/Physics-PET/MR – Making it Clinical
	08:00 - 08:25	Claes Ladefoged (Copenhagen): Attenuation Correction - Is it Solved?
	08:25 - 08:45	Ian Law (Copenhagen): Brain Tumours
	08:30 - 09:00	Nicola Pavese (London): Brain PET and SPECT Imaging in Lewy Body Diseases
	08:30 - 09:00	Cathy Cutler (SNMMI, Upton): Development of Novel Theranostics
	08:45 - 09:05	Alexander Hammers (London): Epilepsy - What does Simultaneous PET-MR Achieve that PET+MR does not?
	09:05 - 09:30	Alexander Drzezga (Cologne): Dementia
	09:00 - 09:30	Jacques Barbet (Nantes): Pretargeting in the Context of Theranostics and Companion Diagnostics
	09:00 - 09:30	Javier Arbizu (Pamplona): Brain SPECT and PET in Tau-Related Parkinsonism
	11:30 - 13:00	Bone & Joint-Skeletal Scintigraphy Today – Accurate Diagnosis of Bone Disease with Therapeutic Impact
	11:30 - 11:50	Philipp Ritt (Erlangen): High Resolution SPECT/CT and Beyond
	11:30 - 13:00	CME 10-Neuroimaging-Brain PET and SPECT in Dementia – Beyond Alzheimer’s Disease
	11:50 - 12:10	Torsten Kuwert (Erlangen): SPECT/CT Quantification
	12:10 - 12:40	Zohar Keidar (Haifa): The End of Planar: Whole-Body SPECT as New Paradigm
	12:40 - 13:00	Gopinath Gnanasegaran (London): Top Ten Diagnoses Made Possible by SPECT/CT
	14:30 - 16:00	Do.More–Committee Symposium-Dosimetry-Validation of Quantitative Imaging, Dosimetry & Estimates of Uncertainty
	14:30 - 14:50	Frédéric Courbon (Toulouse): The Need for Dosimetry Validation - A Clinician’s
	14:50 - 15:10	Johan Ruben Gustafsson (Lund): The Use of Monte Carlo for Validation and Uncertainty Analysis
	15:10 - 15:30	Jonathan Gear (London): Propagation of Uncertainty Analysis for Absorbed Dose Calculations
	15:30 - 15:50	Andrew Robinson (Teddington): Validation of Calibration Protocols and the
	16:30 - 18:00	CME 8-Radionuclide Therapy/Radiopharmacy/Dosimetry-Clinical Trial Design for Radionuclide Therapy
	17:30 - 18:00	Rebecca Gregory (London): Dosimetry for Clinical Trials
Wednesday, October 25, 2017
	08:00 - 09:30	CME 13-Dosimetry/Radionuclide Therapy/Radiation Protection-Treatment Planning for Radionuclide Therapy, How Simple Can it Be?
	08:45 - 9:05	Samer Ezzidin (Homburg): Are Traditional Fixed Activity Schedules Appropriate for Advancing in Personalised Medicine?
	09:05 – 9:20	Katarina Sjögreen Gleisner (Lund): Examples of Workflow and Requirements for Patient-Specific Dosimetry-Guided Treatments

Nous contacter

Services et support

Symbia Intevo Bold is not commercially available in some countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Biograph Horizon Flow edition, Symbia Intevo Bold and xSPECT Quant for 123I, 131In and 177Lu are not commercially available in some countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

For patients up to 227 kg (500 lb).

177Lu is not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.